Portfolio by Johnny RiceInformatics demo
ClariTrial

IRF5

Transcription FactorKymera Only (TPD)

Interferon Regulatory Factor 5

Protein length
504 aa
ChEMBL activities
74
Disease areas
4
Kymera program
Phase 1

IRF5 is a master transcription factor controlling innate and adaptive immune responses via TLR7/9 and other pattern recognition pathways. It drives pro-inflammatory cytokine production (TNFα, IL-6, IL-12, IL-23), type I interferon signaling, and B-cell differentiation toward plasma cells. Human genetics firmly links IRF5 to lupus (SLE) and other autoimmune diseases. No approved IRF5-targeted therapy exists — it has never been drugged.

Key Facts

  • First IRF5-targeted therapy in clinical development — ever
  • IRF5 GWAS risk variants identified in SLE, Sjögren's, RA, IBD, systemic sclerosis
  • No approved or investigational IRF5-targeted therapy in any modality
  • Wholly owned by Kymera — high partnership/out-licensing potential
  • Phase 1 HV study planned Q1 2026; readout expected H2 2026
  • IRF5 drives both type I IFN axis and pro-inflammatory cytokine axis

Mechanism of Action

IRF5 exists in an inactive cytoplasmic conformation maintained by auto-inhibitory interactions between its DBD and IAD2 domains. Activation requires: (1) TLR7/9 or MyD88-dependent signaling triggers K63-ubiquitination and IRAK1/TRAF6-mediated phosphorylation; (2) IRF5 dimerizes; (3) nuclear translocation drives type I IFN gene expression (IFN-α/β), pro-inflammatory cytokines (TNFα, IL-6, IL-12, IL-23), and chemokines. In B-cells, IRF5 additionally drives plasma cell differentiation and antibody class switching. The multiple activation steps and lack of a canonical ATP-binding domain have made IRF5 historically undruggable.

Signaling Pathway

1
Pattern recognition
Viral ssRNA or CpG DNA activates TLR7 or TLR9 in endosomes of plasmacytoid dendritic cells (pDCs), macrophages, and B-cells.
2
MyD88/IRAK4 recruitment
TLR7/9 signal through MyD88 → IRAK4 → IRAK1/TRAF6 signaling axis (shared with IRAK4 pathway).
3
IRF5 post-translational activation
IRAK1 and TRAF6 trigger K63-ubiquitination of IRF5. Multiple phosphorylation sites (S425/S427/S430, S436) are modified, disrupting auto-inhibitory intra-molecular interactions.
4
IRF5 dimerization and nuclear translocation
Activated IRF5 forms homodimers or heterodimers with IRF3/IRF7, which translocate to the nucleus.
5
Type I IFN and cytokine production
Nuclear IRF5 binds IFN-stimulated response elements (ISREs) and NF-κB-like elements to drive IFN-α/β, TNFα, IL-6, IL-12p40, IL-23p19, and BAFF expression.
6
Adaptive immune amplification
BAFF and IL-12/23 from macrophages and pDCs drive autoreactive B-cell survival, plasma cell differentiation, and Th1/Th17 polarization — the cellular basis of lupus nephritis and other autoimmune manifestations.

Why Degradation

IRF5 has no traditional small-molecule binding pocket — no kinase domain, no deep hydrophobic groove accessible with drug-like molecules. The DBD (DNA-binding domain) is shallow; the IAD2 dimerization interface is large and flat. PROTAC degradation is uniquely suited: the degrader molecule doesn't need to inhibit function, only bind with sufficient affinity for ternary complex formation with an E3 ligase. KT-579 is the first IRF5-targeted molecule to reach human trials.

Previously Attempted Approaches

No therapeutic agents targeting IRF5 have reached the clinic in any modality. Attempted approaches in research settings include: DBD-targeting small molecules (failed due to shallow surface), IAD2 inhibitors (low affinity, poor cellular activity), antisense oligonucleotides (delivery challenges). KT-579 represents the first human clinical attempt at IRF5 targeting.

Compound Potency (ChEMBL)

pChEMBL = −log₁₀(IC₅₀). Higher value = more potent. Dashed line = 100 nM threshold. Showing top binding compounds in ChEMBL (74 total activities).

View all 74 activities on ChEMBL

Kymera Program

Phase 1
KT-579

Potentially the first IRF5-targeted therapy ever to enter human trials. IRF5 is a strong genetic risk factor for lupus and multiple other autoimmune diseases per GWAS studies. No approved or investigational IRF5-targeted therapy exists in any modality. KT-579 is wholly owned by Kymera.

Clinical Data

Preclinical data only; Phase 1 HV study planned Q1 2026. First-in-human readout expected H2 2026.

Active Trials
Phase 1 HV Study
NCT07412288
Healthy Volunteers · Phase 1
Data: H2 2026
Target Indications
Lupus (SLE)Sjögren's SyndromeRheumatoid ArthritisSystemic SclerosisDermatomyositisIBD
Full Kymera Profile

Competitive Context

No TPD Competitors

No other company has a targeted protein degrader program against IRF5 in the clinic. Kymera holds first-mover advantage in this target.

View full TPD landscape

Clinical Endpoints

SLEDAI-2KSystemic Lupus Erythematosus Disease Activity Index 2000

Primary disease activity composite for SLE trials. Responder threshold: SLEDAI reduction ≥4 from baseline.

BICLABritish Isles Lupus Assessment Group (BILAG)-based Combined Lupus Assessment

Composite SLE response measure used in Phase 2/3 trials including anifrolumab (Saphnelo).

SRI-4SLE Responder Index 4

Composite measure requiring SLEDAI-2K ≥4 reduction plus no worsening in BILAG or physician assessment.

IFN gene signatureType I Interferon Gene Signature Score

Pharmacodynamic biomarker measuring IFIT1, IFIT2, IFIT3, IFI27 expression in whole blood. Used to stratify patients and measure target engagement.

ESSDAIEULAR Sjögren's Syndrome Disease Activity Index

Primary endpoint for Sjögren's trials, covering 12 organ domains.

Disease Context

Total patient potential: Tens of millions globally across lupus, Sjögren's, RA, systemic sclerosis, and related autoimmune diseases

Systemic Lupus Erythematosus (SLE)
Prevalence
1.5M in the US; 5M globally. ~90% female.
Market Leader
Benlysta (belimumab), Saphnelo (anifrolumab), hydroxychloroquine
Unmet Need
Lupus nephritis progresses to ESRD in ~20% of patients. Current biologics don't address the IRF5-driven innate immune/type I IFN arm comprehensively. Oral therapy would transform disease management.
Sjögren's Syndrome
Prevalence
~4M in the US; predominantly middle-aged women
Market Leader
No approved disease-modifying therapies — only symptom management
Unmet Need
IRF5 is a strong genetic risk factor for Sjögren's. No approved therapy exists. First mover advantage would be significant.
Rheumatoid Arthritis (RA)
Prevalence
1.3M US; driven partly by IRF5-dependent macrophage polarization
Market Leader
Humira, Enbrel, Rinvoq, Orencia
Unmet Need
IRF5 drives M1 macrophage polarization and synovial inflammation. Could complement existing therapies or serve non-responders.
Systemic Sclerosis / Dermatomyositis
Prevalence
~100,000 US each
Market Leader
No approved targeted biologics for systemic sclerosis
Unmet Need
High unmet need, orphan indications, strong type I IFN signature. IRF5 GWAS hits in both diseases.
Search PubMed for IRF5 literature
IRF5 lupus GWAS · IRF5 autoimmune transcription factor
Open PubMed